Literature DB >> 25560529

Glioma in 2014: unravelling tumour heterogeneity-implications for therapy.

David A Reardon1, Patrick Y Wen1.   

Abstract

Heterogeneity within and across tumours is increasingly recognized as a critical factor that limits therapeutic progress for many cancers. Key studies reported in 2014 describe previously unappreciated patterns of geographical and temporal heterogeneity for glioblastoma (the most-common primary CNS tumour in adults), with important implications for ongoing therapeutic studies evaluating molecular targeted therapies.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25560529     DOI： 10.1038/nrclinonc.2014.223

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Authors:  Walter Taal; Hendrika M Oosterkamp; Annemiek M E Walenkamp; Hendrikus J Dubbink; Laurens V Beerepoot; Monique C J Hanse; Jan Buter; Aafke H Honkoop; Dolf Boerman; Filip Y F de Vos; Winand N M Dinjens; Roelien H Enting; Martin J B Taphoorn; Franchette W P J van den Berkmortel; Rob L H Jansen; Dieta Brandsma; Jacoline E C Bromberg; Irene van Heuvel; René M Vernhout; Bronno van der Holt; Martin J van den Bent
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

2.  Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Authors:  Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

3.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

9.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079
  9 in total
  41 in total

Review 1.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

2.  An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells.

Authors:  María Sánchez-Osuna; Laura Martínez-Escardó; Carla Granados-Colomina; Fina Martínez-Soler; Sònia Pascual-Guiral; Victoria Iglesias-Guimarais; Roser Velasco; Gerard Plans; Noemi Vidal; Avelina Tortosa; Carlos Barcia; Jordi Bruna; Victor J Yuste
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

3.  [Molecular imaging in neurological diseases].

Authors:  M Reimold; C la Fougère
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

4.  Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.

Authors:  Yu Shi; Wenchao Zhou; Lin Cheng; Cong Chen; Zhi Huang; Xiaoguang Fang; Qiulian Wu; Zhicheng He; Senlin Xu; Justin D Lathia; Yifang Ping; Jeremy N Rich; Xiu-Wu Bian; Shideng Bao
Journal:  Cell Death Differ       Date:  2016-10-14       Impact factor: 15.828

5.  Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.

Authors:  Yuji Piao; Soon Young Park; Verlene Henry; Bryan D Smith; Ningyi Tiao; Daniel L Flynn; John F de Groot
Journal:  Neuro Oncol       Date:  2016-03-09       Impact factor: 12.300

6.  Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.

Authors:  Zhi-Cheng Li; Hongmin Bai; Qiuchang Sun; Qihua Li; Lei Liu; Yan Zou; Yinsheng Chen; Chaofeng Liang; Hairong Zheng
Journal:  Eur Radiol       Date:  2018-03-21       Impact factor: 5.315

7.  Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience.

Authors:  Otto M Henriksen; Vibeke A Larsen; Aida Muhic; Adam E Hansen; Henrik B W Larsson; Hans S Poulsen; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-12       Impact factor: 9.236

8.  Clinical and prognostic significance of HIF-1α in glioma patients: a meta-analysis.

Authors:  Qi Liu; Peicheng Cao
Journal:  Int J Clin Exp Med       Date:  2015-12-15

9.  Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.

Authors:  Esther P Jane; Daniel R Premkumar; Swetha Thambireddy; Brian Golbourn; Sameer Agnihotri; Kelsey C Bertrand; Stephen C Mack; Max I Myers; Ansuman Chattopadhyay; D Lansing Taylor; Mark E Schurdak; Andrew M Stern; Ian F Pollack
Journal:  Mol Cancer Res       Date:  2020-04-01       Impact factor: 5.852

10.  Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance.

Authors:  Haohao Huang; Songyang Zhang; Yuanyuan Li; Zhaodan Liu; Lanjuan Mi; Yan Cai; Xinzheng Wang; Lishu Chen; Haowen Ran; Dake Xiao; Fangye Li; Jiaqi Wu; Tingting Li; Qiuying Han; Liang Chen; Xin Pan; Huiyan Li; Tao Li; Kun He; Ailing Li; Xuemin Zhang; Tao Zhou; Qing Xia; Jianghong Man
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.